India’s Biocon Wins 1st Biosimilar Approval Of Herceptin; Will Launch Before March 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
As the decks are cleared for an India launch of trastuzumab, Biocon and its global partner Mylan will be watched closely by both local and global competitors. The market impact in India will be most significant in terms of price, and it will test if Roche has played its cards right by aligning with local company Emcure.
You may also be interested in...
Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on
MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.